Why Your Valuation Is a Narrative, Not a Number
Round Ready Academy — Lesson 1 of 11
Founders tend to treat valuation as a number to be argued for. Institutional investors treat it as a conclusion to be underwritten. The gap between those two views explains most of the pain, surprise, and re-pricing that happens in the run-up to a Series A or B round.
This lesson starts where the Round Ready Academy begins: with the unglamorous reality that the price of your next round is decided less by your pitch deck and more by the evidence you can put behind it. The Opagio 12 is the structured language for that evidence.
Institutional investors underwrite evidence and narrative — not pitch decks alone. The deck opens the meeting. The evidence bundle closes the round. Founders who only prepare the deck are arguing a position. Founders who prepare both are negotiating from a defensible one.
What Institutional Investors Actually Do Before They Price a Round
At angel and pre-seed, valuation is a negotiation between conviction and dilution. The cheque writer is often backing a person and a thesis. Evidence matters, but the bar is low because the stage is early.
At Series A and beyond, the economics change. An institutional partner is writing a fiduciary cheque on behalf of a fund, a pension scheme, or a family office. Every term sheet has to be defensible to an investment committee (IC). The IC will not have met you. They will read what the lead partner wrote, which will be shaped by what the diligence process produced, which will in turn be shaped by what you gave them.
The process, compressed into one diagram, looks like this:
What Happens Between First Meeting and Term Sheet
| Stage | What the investor is doing | What they need from you |
|---|---|---|
| Screen | Deciding whether this is ICP for the fund | Deck, traction summary, sector thesis |
| Partner meeting | Testing whether the thesis survives a conversation | Clear narrative, commercial logic, market framing |
| Diligence | Building the evidence bundle that the IC will read | Asset base, customer cohorts, metrics tree, team, IP |
| IC | Pricing the round against the bundle plus the fund's portfolio strategy | Pre-built answers to every IC objection |
| Term sheet | Codifying the price and structure | Your negotiation is now about terms, not price |
The partner you have been meeting with is not the person who decides your price. The IC is. And the IC reads evidence, not enthusiasm.
The Pitch Deck Is Marketing. The Evidence Bundle Is the Underwrite
Two founders with the same ARR, the same growth rate, and the same team can close Series A rounds at very different valuations. The variable is almost never the deck. The variable is what sits behind the deck.
Think of the round like an underwriting decision. A lender does not extend credit on a cover letter. An insurer does not price a policy on a summary. A Series A partner does not price your round on 14 slides.
Two UK-based SaaS companies closed Series A rounds within three months of each other in 2024. Both had £1.6M ARR, 110% net retention, and strong founder teams. Company A closed at £12M pre-money on a defended Opagio 12 profile, a 47-question diligence corpus, and a live customer cohort file. Company B closed at £7M pre-money on a deck, three case studies, and a set of partial metrics. The IC memos tell the story: Company A "had answers to every line item before we asked"; Company B "left gaps the partner had to fill with assumption." Same business, different evidence bundle, different price.
The deck is how you get the meeting. The evidence bundle is how you keep the price.
The Two Halves of a Priced Round — Evidence and Narrative
Evidence alone does not close a round. A list of facts, however well-organised, is not a thesis. Narrative alone does not close a round either. A beautiful story, however well-told, will not survive the IC if it is not backed by something.
Every priced round is built on the interaction of two halves.
Evidence
- Customer cohorts by vintage and segment
- Retention and contribution margin data
- Asset register — the Opagio 12 mapped to your business
- Team composition, attrition, key-person exposure
- Contracts, IP ownership, data rights, regulatory position
Narrative
- Why this market, why now
- Why your team is the right team
- What compounds as you scale
- What the next round will look like if this one closes
- The answer to "why is this not a feature?"
Weak evidence plus strong narrative produces enthusiasm that does not survive diligence. Strong evidence plus weak narrative produces a thorough but uninspiring memo. The round that closes at the top of the range has both.
Why The Opagio 12 Is the Structured Language for the Evidence Half
Investors evaluate a lot of companies. They do not have the bandwidth to learn a new vocabulary for each one. The more your evidence maps to a framework they already recognise, the less friction there is between what you have built and what they are willing to price.
The Opagio 12 is our name for the twelve intangible asset categories that institutional investors, and by extension their diligence teams and valuation experts, actually care about at Series A and B. They are:
The Opagio 12 — at a glance
| # | Driver | What it answers for an investor |
|---|---|---|
| 1 | Brand and Reputation | Will a customer choose you over an unbranded alternative? |
| 2 | Customer Capital | What is the quality of your revenue base and its retention profile? |
| 3 | Network Effects and Platforms | Does value compound as the user base grows? |
| 4 | Technology and Innovation | What technical capability is proprietary versus commoditised? |
| 5 | Data and Intelligence | What datasets do you own, and what decisions do they enable? |
| 6 | Human Capital | Who knows the things that make this business work? |
| 7 | Organisational Capital | What survives if any one person leaves? |
| 8 | Ecosystem and Partnerships | Who else is invested in your success? |
| 9 | Content and IP | What is legally protectable or already protected? |
| 10 | Regulatory and Compliance | What permissions do you hold that others would need years to earn? |
| 11 | Switching Costs and Lock-In | How painful is it for a customer to leave? |
| 12 | Culture and Ways of Working | What habits produce outcomes that numbers alone cannot explain? |
No investor uses the phrase "the Opagio 12" across a diligence call. They do, however, ask about every one of these categories in some form. When you have evidence organised by driver, you can answer in the order the partner asks, not in the order your deck is structured. That single shift materially changes how the meeting feels.
The First Thing to Build Before Your Next Round
You do not have to build the full evidence bundle in one sitting. But you do need a structured, auditable starting point — a record of what you have, against a framework the investor already understands.
That is what a Value Drivers Register is. It is the output of the Discover and Assess steps of the Opagio Method, and it is the document institutional founders are increasingly arriving at first meetings with. It replaces "trust me" with "here is the register, happy to walk you through it."
Where to Start, in Plain Terms
Run the Round Readiness Diagnostic. It produces a one-page view of how your business scores against The Opagio 12, where the evidence is strong, where the gaps are, and which driver is most worth strengthening before your next round. The diagnostic is free and takes about twenty minutes.
Every subsequent lesson in this course assumes you have run it, because the diagnostic tells you which of the next ten lessons is most worth reading first.
You can also learn more about the framework itself in our guide to The Opagio 12 and the Value Drivers Register. See Lesson 2: The 12 things buyers actually price for the driver-by-driver walkthrough. Or start from the Round Ready Academy overview if you want to see the full syllabus first.
The diagnostic is a starting point, not a finished assessment. Founders who take it seriously treat the output as a working document to discuss with their team, their chair, and their existing investors — not as a score to celebrate or dispute. The register lives; it is not delivered.
What the Rest of the Course Will Do
Every subsequent lesson in the Round Ready Academy translates one part of this evidence-and-narrative idea into something you can act on:
- Lesson 2 walks through all twelve drivers with sector examples.
- Lesson 3 surfaces the specific blind spots £1M+ ARR founders tend to have.
- Lessons 4 to 8 cover the shift from pre-institutional to institutional capital — what changes, what the Series A asset register looks like, how to design your metrics tree, how to make a bridge decision, and how to handle a lowball offer.
- Lessons 9 and 10 cover Series B efficiency and IP-backed lending as a non-dilutive option.
- Lesson 11 is a synthesis — your 90-day round-ready plan.
You do not need to complete every lesson to benefit. You do need to complete the ones that match where your business is, starting from the diagnostic output.
The Round-Ready Mindset in One Sentence
If the remainder of this course leaves you with one mindset shift, let it be this: the price of your next round is the conclusion your investor's IC can defend with the evidence you provided.
Every further lesson is about improving that evidence.
Primary CTA: Run the Round Readiness Diagnostic to get your starting Opagio 12 profile and the gap list that tells you which lesson is most worth reading first.
Mark Hillier is Co-Founder and CCO of Opagio. Thirty years of commercial growth and PE exit work across financial services, property, and technology, with a particular focus on how institutional investors underwrite intangible value. Meet the team.
Lesson 1 Quiz
Check your understanding of this lesson.